StreetAlpha.app
Home › Stocks › ARQT

Arcutis Biotherapeutics, Inc. (ARQT)

Healthcare
$26.36
▼ −2.98%
LAST CLOSE · NOV 20

Arcutis Biotherapeutics develops and sells ZORYVE topical treatments for psoriasis, atopic dermatitis, and seborrheic dermatitis. It last closed at $26.36 on Nov 20, down 2.98% on the day. The next earnings report for ARQT is expected around Wed, Feb 24, 2027, after the close. For the quarter ended Sep 2026, ARQT reported EPS of $0.06 on revenue of $143.9M, with revenue up 45.1% from a year ago. Over its last 8 reports the stock moved an average of 9.8% the session after earnings. Over the last 12 months ARQT insiders bought $0 of stock on the open market and sold $14.0M, according to SEC Form 4 filings.

AI Auto Pilots
Is ARQT in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ARQT.

Key Stats

Last 12 months
Results
Revenue
$508.7M
+60.0% vs a year ago
Net income
$29.9M
5.9% margin
EPS (diluted)
$0.22
Free cash flow
$59.7M
11.7% margin
Valuation
Market cap
$3.3B
126.5M shares
P/E
119.8
Price over 12 month EPS
Price to sales
6.6
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$33.4M
At Sep 30
Debt
$109.4M
At Sep 30
Shareholder equity
$244.0M
Shares outstanding
126.5M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $0$0FY2021FY2022: $3.7M$3.7MFY2022FY2023: $59.6M$59.6MFY2023FY2024: $196.5M$196.5MFY2024FY2025: $376.1M$376.1MFY2025

From ARQT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
Feb 24
Estimated date · After the close
Reported EPS
$0.06
Quarter ended Sep 2026
Year ago EPS
$0.06
+0.0% on a GAAP basis
Revenue
$143.9M
+45.1% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.08Dec '24Mar 2025: -$0.20Mar '25Jun 2025: -$0.13Jun '25Sep 2025: $0.06Sep '25Dec 2025: $0.13Dec '25Mar 2026: -$0.09Mar '26Jun 2026: $0.11Jun '26Sep 2026: $0.06Sep '26Latest $0.06
Revenue by quarter
Dec 2024: $71.4MDec '24Mar 2025: $65.8MMar '25Jun 2025: $81.5MJun '25Sep 2025: $99.2MSep '25Dec 2025: $129.5MDec '25Mar 2026: $105.4MMar '26Jun 2026: $129.9MJun '26Sep 2026: $143.9MSep '26Latest $143.9M
How ARQT moved after its last 8 reports
Average move the session after a report ±9.8%
Nov 4, 2026After the close−20.7%
Aug 5, 2026After the close−2.5%
Feb 25, 2026After the close+5.8%
Oct 28, 2025Time not announced+27.0%
Aug 6, 2025After the close−8.1%
May 6, 2025After the close−4.3%
Feb 25, 2025After the close+8.4%
Jan 13, 2025Time not announced−1.3%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on ARQTStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on ARQT
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on ARQT

Technical Analysis

ARQT · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend

The stock is 10% below its 20 day and 6% below its 50 day average. It is 4% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 42). The nearest support is the swing low (Jul 13) at $26.01, and the nearest resistance the Pivot at $26.70.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityHigh, 5.8%/day
Key levels
$34.8052 week high+32.0%
$29.1120 day average+10.4%
$27.8650 day average+5.7%
$27.12Pivot R1+2.9%
$27.01100 day average+2.5%
$26.97Swing high (Oct 9)+2.3%
$26.70Pivot+1.3%
$26.36Last close
$26.01Swing low (Jul 13)−1.3%
$25.94Pivot S1−1.6%
$25.41200 day average−3.6%
$19.3052 week low−26.8%
Indicators
RSI (14)42.44Middle of its rangeNeutral
MACD-0.48Below its signal lineBearish
Stochastic19.0Near the bottom of its rangeOversold
ADX (14)18.0No clear trend
Williams %R-88.2Oversold below −80, overbought above −20Oversold
CCI (20)-70.6Oversold below −100, overbought above 100Neutral
Rate of change+3.2%Change over 10 sessionsBullish
ATR (14)$1.53Typical daily range, 5.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for ARQT

What happened before

See how ARQT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow ARQT usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How ARQT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for ARQTHow many large options trades hit ARQT, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

ARQT Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲185 buying vs 110 selling
  • ▲Held by funds +15.5 pts
  • ▲Funds holding +21
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding294273+7.7%
In funds' top 1065+20.0%
Held by funds119.5%103.9%+15.5 pts
New / increased61 / 12440 / 95+37.0%
Reduced / sold out68 / 42101 / 38−20.9%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ARQT institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

ARQT Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$14.0M49 sales · 10 insiders
80% of the selling was under pre-arranged trading plans.
2025-12 sold $735K2026-01 sold $362K2026-02 sold $2.2M2026-03 sold $2.8M2026-04 sold $239K2026-05 sold $493K2026-06 sold $237K2026-07 sold $127K2026-08 sold $1.7M2026-09 sold $456K2026-10 sold $127K2026-11 sold $1.7MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 16Howard G. WelgusDirectorSale plan4,728$28.16$133K
Nov 4Masaru MatsudaEVP, Chief Legal OfficerSale plan41,219$34.24$1.4M
Nov 2Todd WatanabeSee RemarksSale4,377$31.86$139K
Nov 2Patrick BurnettEVP, Chief Medical OfficerSale943$31.86$30K
Oct 15Howard G. WelgusDirectorSale plan4,728$26.93$127K
Sep 16Masaru MatsudaSee RemarksSale plan3,674$25.00$92K
Every insider buy and sale for ARQT over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See ARQT insider trades →

From SEC Form 4 filings by ARQT's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ARQT is in one of them and how their past ARQT trades turned out.

ARQT in the AI portfolios
Loading…

ARQT News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ARQT in an article yet. Here's the latest on the wider market.

ARQT in the news

ARQT Congress Trades

All congress trades →
Trades, 12 months
3
Buys
2
67%
Sells
1
33%
People
1
Last filed Jun 8
Who traded ARQT · since 2022
Latest 5 filings of 6
$1K – $15KTraded May 29, 2026Filed Jun 8, 2026
$1K – $15KTraded Mar 3, 2026Filed Apr 7, 2026
Gilbert CisnerosSell (partial)
$1K – $15KTraded Dec 11, 2025Filed Jan 12, 2026
$1K – $15KTraded Sep 15, 2023Filed Oct 15, 2023
$1K – $15KTraded Apr 17, 2023Filed May 19, 2023
PersonTypeAmountTradedFiledDelay
Gilbert CisnerosD · CABuy$1K – $15KMay 29, 2026Jun 8, 202610 d
Gilbert CisnerosD · CABuy$1K – $15KMar 3, 2026Apr 7, 202635 d
Gilbert CisnerosD · CASell (partial)$1K – $15KDec 11, 2025Jan 12, 202632 d
Josh GottheimerD · NJSell$1K – $15KSep 15, 2023Oct 15, 202330 d
Josh GottheimerD · NJBuy$1K – $15KApr 17, 2023May 19, 202332 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Arcutis Biotherapeutics

Arcutis Biotherapeutics is a biopharmaceutical company based in Westlake Village, California. It develops and sells treatments for skin conditions, mainly its ZORYVE line of topical creams and foam. These products treat plaque psoriasis, atopic dermatitis, and seborrheic dermatitis in children and adults. Its customers include dermatologists, primary care practitioners, and pediatricians who prescribe them.

Headquarters
Westlake Village, CA